PV Virtual trainings during covid-19 pandemic

R. Soulaymani
Since 2007, the RCC have been providing pharmacovigilance training to African and EMR countries.

Our flagship annual course took place in Morocco for two weeks.

The team have been travelling our the world to provide training on Pharmacovigilance process tools, methods and technics.

Due to the Covid-19 epidemic and the restriction it has enforced, the digitalization of the course emerged as an obvious choice.

With the success of the course online version, we decided to develop more courses and train more people around the globe.
This course aims to promote patient safety through the development of (1) knowledge, (2) skills and (3) abilities of health professionals in the field of adverse reaction management of health products (drugs, vaccines, medical devices, medicinal plants, etc...) and in the field of development of Pharmacovigilance centers and systems.

This version has been developed to meet the countries’ need in terms PV training, to respond to the growing demand of health care professionals and to ensure the continuity of a training launched 15 years ago.
## OUR TRAININGS
**On Anti-Covid-19**

<table>
<thead>
<tr>
<th></th>
<th>Basic</th>
<th>Intermediate</th>
<th>Advanced</th>
<th>ToT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Target audience</strong></td>
<td>HCPs at vaccination sites</td>
<td>HCPs responsible for implementing the vaccine strategy (immunization program, regulatory body, national and regional pharmacovigilance centers, vaccination committees)</td>
<td>Pharmacovigilance professionals &amp; Investigation team</td>
<td>HCPs responsible for implementing the vaccine strategy + pharmacovigilance professionals</td>
</tr>
<tr>
<td><strong>Prerequisites</strong></td>
<td>Basic health science training</td>
<td>All the skills learnt in basic level</td>
<td>All the skills learnt in intermediate level</td>
<td>Followed the intermediate course</td>
</tr>
<tr>
<td><strong>Skills taught</strong></td>
<td>Identify an AEFI Manage a patient Notify an AEFI Communicate around AEFIs Communicate with NPV</td>
<td>Collect AEFI reports Conduct an AEFI causality assessment Provide feedback to reporter Add a case in vigiflow</td>
<td>Investigate AESIs Detest signals and conduct a literature review Exploit vigiflow data for reports Conduct an AEFI committee Develop and deliver a training program</td>
<td>How to deliver the basic trainings to HCP at vaccination sites</td>
</tr>
<tr>
<td>Date</td>
<td>Event Description</td>
<td>Participants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------</td>
<td>---------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>June 2020</td>
<td>14th CIP module 1, Fr : 68 participants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>September 2020</td>
<td>14th CIP module 2, Fr : 47 participants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>March 2021</td>
<td>14th CIP module 3, Fr : 40 participants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>May 2021</td>
<td>VAC Int, Fr : 49 participants</td>
<td>TDRCOACHING : 27 participants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>June 2021</td>
<td>15th CIP module 1, Fr : 82 participants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>July 2021</td>
<td>TDR, Eng : 26 participants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>September 2021</td>
<td>15th CIP module 2, Fr : 59 participants</td>
<td>VAC Int, Fr : 230 participants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>October 2021</td>
<td>15th CIP module 3, Fr : 51 participants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>January 2022</td>
<td>VAC Int, Fr : 43 participants</td>
<td>VAC Basic, Eng : 27 participants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>February 2022</td>
<td>VAC Int, Eng : 40 participants</td>
<td>ToT Basic, Fr : 9 participants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>April 2022</td>
<td>VAC Adv, Eng : 25 participants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>May 2022</td>
<td>16th CIP module 1, Fr : 102 participants</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
• Total number of participants: 831
• Total number of countries: 38
• Many participants have participated to several courses (e.g. CIP, VAC Basic, Intermediate, Advanced and ToT)

### Quality
- Administrators: 2%
- Academics: 2%
- Nurses: 9%
- Doctors: 37%
- Pharmacists: 41%
- Others: 9%

### Sex ratio
- H: 43%
- F: 57%
UPCOMING TRAININGS

- Safety of medicinal product during pregnancy (July 4th to 8th):
  - At the time of market authorization, and despite the lack of information on the safety of use of drugs and vaccines in pregnant women, drug intake by expectant mothers is a reality and can have an impact on the outcome of the pregnancy or on the organic and functional development of the embryo, fetus or newborn.

- Active safety surveillance training course (July 13th to 15th):
  - The objectives of this module are twofold. First to introduce the active safety surveillance to the participants, then to provide them with the process and tools to carry it out.
The trainings provided by the RCC got important impacts in terms of:

- **Participants**: we are able to accommodate more participants than during online trainings (e.g. 20 participants for on-site version of CIP vs. 100 participants for online version).
- **Number of trainings**: since the travel barrier was lifted we were able to conduct multiple trainings over the same month or period of time.
- **Targeted countries**: we were able to accommodate different countries with no visa or travel constrains and some for the first time (Togo, Comoros...).
- **Languages**: while we primarily trained in English, we were able to develop courses in other languages.
- **Contents**: since time is no longer a constraint, we were able to construct more technical curricula (e.g. 2-week training for on-site version of CIP vs. 6-week training for online version).
- **Community**: Thanks to these trainings and the online interactions we created, a worldwide pharmacovigilance community was built allowing scientific and information sharing.
IMPACT

Jaber Jaber - 2nd
Pharmacovigilance Consultant / Head of Rational Drug Use

Your efforts are highly appreciated such an informative well designed course from the experts in Rabbat collaborating Center looking forward to collaborating more.

Like · 📢 13 · Reply

Dana Samih Ahmad - 2nd
Assistant Pharmacovigilance specialist

Thank you all at RCC for your excellent training, it was my pleasure to participate in the three levels of this training, it was very fruitful and strengthened our knowledge in the field, I was also very glad to meet great trainees from different parts of the world. Eid Mubarak ...

Like · 📢 11 · Reply

Manal Younus - 2nd
Head of Iraqi Pharmacovigilance Center | ISoP Advisor...

Thank you so much for all the colleagues at the Rabat CC, specially Dr. Rachida, Houda, Afaf, Ghita, Emame, Loubna, Saadia and all who worked behind the stage to make this training model a hit by all measures.
The learning atmosphere, the colleagueous and consistency of all the trainers and trainees build this real story of success. Looking forwards for more😊😊😊😊

Like · 📢 13 · Reply

Abdul Mateen - 2nd
Assistant Director (RO-12) at Drug Regulatory Author...

Without any doubt, it was the best virtual training I ever attended. It felt like face to face training even though it was an virtual training session due to frequent interaction, a lots of homework, and use of new sophisticated tools.

All praise to RCC team.
Follow our LinkedIn page and Instagram account to stay aware of our upcoming trainings.